RxDoctor Payments Data

Trupti Nadkar, MD

Family Medicine · Montgomery, ALNPI 1073979456

Payments from drug & device makers

$1,525in general payments, 2019–2025

Across 85 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$281
  • Pfizer$147
  • Neurocrine Biosciences, Inc.$145
  • GSK$121
  • Novo Nordisk$116
  • AstraZeneca$99
  • plus $617 from 19 others

What the payments were for

  • Food & beverage$1,525100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,525 in reported general payments places this provider in the 60th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$47,756
Medicare patients
181
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide118$127,943
JardianceEmpagliflozin105$125,038
OzempicSemaglutide99$116,323
EliquisApixaban104$96,631
FarxigaDapagliflozin Propanediol62$75,486
JanuviaSitagliptin Phosphate43$44,231
XareltoRivaroxaban45$36,837
EntrestoSacubitril/Valsartan32$36,261
TradjentaLinagliptin32$35,920
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$29,378
MounjaroTirzepatide21$22,797
LinzessLinaclotide25$21,298
Spiriva HandihalerTiotropium Bromide16$16,040
MyrbetriqMirabegron16$12,120
Janumet XrSitagliptin Phos/Metformin Hcl14$11,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$84$168,219151 claims
Lilly USA, LLCTrulicity, Mounjaro$14$150,740139 claims
Novo NordiskOzempic$116$116,32399 claims
PfizerEliquis$147$96,631104 claims
AstraZenecaFarxiga, Symbicort, Brilinta$99$90,256108 claims
MerckJanuvia, Janumet Xr$17$56,13757 claims
GSKTrelegy Ellipta, Breo Ellipta$121$39,07864 claims
Johnson & JohnsonXarelto$281$36,83745 claims
NovartisEntresto$19$36,26132 claims
Astellas Pharma US IncMyrbetriq$14$12,12016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →